摘要
目的对独活寄生汤治疗膝骨关节炎(KOA)的系统评价及meta分析进行再评价。方法检索中国知网、万方数据知识服务平台、维普网、CBM、Pub Med、Web of Science、The Cochrane Library和Prospero,收集独活寄生汤治疗KOA的系统评价及meta分析,检索时限为建库至2022年12月,采用系统综述和meta分析优先报告规范(PRISMA)声明进行报告质量评价,AMSTAR-2量表进行方法学质量评价,GRADE系统进行结局指标证据质量分级。结果共纳入8篇文献,对照组涉及西药、针灸,试验组为单用独活寄生汤和在对照组基础上使用独活寄生汤,8篇文献PRISMA声明得分≥20分,AMSTAR-2量表评价结果显示多个关键条目不达标,文献方法学质量均为极低。GRADE系统的评价结果显示,无高等证据质量,整体证据质量偏低。结论独活寄生汤治疗KOA临床效果的相关meta分析整体方法学和证据质量水平不高,研究结论存在一定局限性,且对安全性方面的评估较少,医师在临床决策的使用中需谨慎,未来相关研究需进一步加强规范性。
Objective To reevaluate the systematic review and meta-analysis of Duhuo Jisheng Decoction in the treatment of knee osteoarthritis(KOA).Methods Systematic reviews and meta-analyses on Duhuo Jisheng Decoction in the treatment of KOA were collected from CNKI,Wanfang Data,VIP,CBM,PubMed,Web of Science,the Cochrane Library,and Prospero.The search period was from inception until December 2022.Preferred reporting items for systematic reviews and meta-analyses(PRISMA)statement was used to evaluate report quality,AMSTAR-2 scale was used to evaluate methodological quality,and GRADE system was used to grade the evidence quality of outcome indicators.Results A total of eight literatures were included,the control group involved western medicine and acupuncture,and the experimental group used Duhuo Jisheng Decoction alone and Duhuo Jisheng Decoction on the basis of the control group.PRISMA statement scores of eight literatures were≥20 points,and the evaluation results of AMSTAR-2 scale showed that many key items were substandard,and the methodological quality of the literatures was extremely low.The evaluation results of the GRADE system showed that there was no high quality of evidence and the overall quality of evidence was low.Conclusion The overall methodology and evidence quality of meta-analysis related to the clinical effect of Duhuo Jisheng Decoction in the treatment of KOA are not high,the study conclusions have certain limitations,and the evaluation of safety is less.Physicians should be cautious in the use of clinical decision-making,and future relevant studies need to further strengthen the standardization.
作者
许月泠
曾兰卿
梁佩文
程桯
孙卫东
胡海威
孙永生
穆晓红
XU Yueling;ZENG Lanqing;LIANG Peiwen;CHENG Ting;SUN Weidong;HU Haiwei;SUN Yongsheng;MU Xiaohong(Department of Osteology,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing100700,China;the Second Department of Osteoarthropathy,Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing100102,China)
出处
《中国医药导报》
CAS
2023年第29期125-131,共7页
China Medical Herald
基金
国家自然科学基金资助项目(81072823)。
